Abstract
To expand the available tools for investigating human sarcomas, we characterized the primary properties of 22 common, uncommon, and newly characterized sarcoma cell lines representing eight different histological subtypes. Throughout the characterization process we noticed that in vitro markers and assays are poor indicators of tumorigenicity and that generated xenografts often bear little resemblance to the original histopathology. In vitro properties examined included morphology, proliferation rate, cell cycle characteristics, invasiveness, and immunohistochemical expression of p53 and phospho-AKT. In vivo properties examined included days to tumor formation in NOD/SCID mice, xenograft morphology in several locations and immunohistochemical expression of Ki67, p53 and phospho-AKT. We believe that such an in depth comparison of a large cohort of sarcoma cell lines will be useful in both designing and interpreting experiments aimed at elucidating both the molecular biology and efficacy of therapeutic agents in sarcomas. However, that data generated also suggests a small set of sarcoma cell lines may be inappropriate for generalizations regarding biological behavior of specific sarcoma subtypes. Integration of functional genomics or other more sophisticated assays of cell lines may help bridge the differences in vitro and in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Li WW, Takahashi N, Jhanwar S et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001; 7: 2908–11.
Leu KM, Ostruszka LJ, Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004; 22: 1706–12.
Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595–602.
Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 corrected. J Clin Oncol 2007; 25: 2755–63.
Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist 2007; 12: 999–1006.
Matushansky I, Maki RG. Mechanisms of sarcomagenesis. Hematol Oncol Clin North Am 2005; 19: 427–49, v.
Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with highdose imatinib: randomised trial. Lancet 2004; 364: 1127–34.
Ando T, Ichikawa J, Okamoto A, Tasaka K, Nakao A, Hamada Y. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res 2005; 23: 964–9.
Graat HC, Witlox MA, Schagen FH et al. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. Br J Cancer 2006; 94: 1837–44.
Walters DK, Muff R, Langsam B, Gruber P, Born W, Fuchs B. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Investig New Drugs 2007; 25: 305–12.
Moneo V, Serelde BG, Fominaya J et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007; 100: 339–48.
Matushansky I, Hernando E, Socci ND et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007; 117: 9.
Chambers JM. Linear models. In: Chambers SJM, Hastie TJ, eds. Statistical Models. Pacific Grove, California: Wadsworth & Brooks/Cole, 1992; 96–138.
Hastie TJ, Pregibon D. Generalized linear models. In: Chambers SJM, Hastie TJ, eds. Statistical Models. Pacific Grove, California: Wadsworth & Brooks/Cole, 1992; 196–246.
Wilkinson GN, Rogers CE. Symbolic descriptions of factorial models for analysis of variance. Appl Stat 1973; 22: 392–9.
Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM, Brennan MF. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 1998; 83: 490–7.
Leach FS, Tokino T, Meltzer P et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231–4.
Latres E, Drobnjak M, Pollack D et al. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 1994; 145: 345–55.
Hernando E, Charytonowicz E, Dudas ME et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Med 2007; 13: 748–53.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mills, J., Matos, T., Charytonowicz, E. et al. Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo . Hum Cell 22, 85–93 (2009). https://doi.org/10.1111/j.1749-0774.2009.00073.x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1111/j.1749-0774.2009.00073.x